Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Krzysztof Nowak

Allergy & Immunology Yonkers, NY Medical Doctor

NPI 1174597793 CMS profile 280414

1086 N Broadway Ste 220, Yonkers, NY 10701

Open in the dashboard

General payments

$14,112

651 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Krzysztof Nowak of Yonkers, NY is reported in the CMS Open Payments database as having received $14,112 across 651 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,562 117
2024 General $2,070 105
2023 General $3,119 141
2022 General $2,354 106
2021 General $1,546 78
2020 General $713 40
2019 General $1,748 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Krzysztof Nowak
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Krzysztof Nowak were reported at $2,562. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Krzysztof Nowak Allergy & Immunology median Middle half National median
2019 $1,748 $594 $163–$1,512 $163
2020 $713 $426 $106–$1,233 $114
2021 $1,546 $638 $157–$1,708 $132
2022 $2,354 $790 $205–$1,961 $149
2023 $3,119 $852 $220–$2,147 $160
2024 $2,070 $865 $203–$2,267 $164
2025 $2,562 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $3,219 133 payments
  2. GlaxoSmithKline, LLC. $2,159 89 payments
  3. Genzyme Corporation $1,581 58 payments
  4. Novartis Pharmaceuticals Corporation $1,298 109 payments
  5. Pfizer Inc. $778 38 payments
  6. AbbVie, Inc. $711 26 payments
  7. OptiNose US, Inc. $675 43 payments
  8. Grifols USA, LLC $454 18 payments
  9. Genentech USA, Inc. $388 14 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $378 17 payments
  11. Other $2,472 106 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,969 648 payments
  2. Education $143 3 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT $2,306 83 payments
  2. NUCALA $1,240 46 payments
  3. TRELEGY ELLIPTA $855 40 payments
  4. FASENRA $831 37 payments
  5. RINVOQ $762 27 payments
  6. TEZSPIRE $702 31 payments
  7. Xhance $675 43 payments
  8. EUCRISA $586 27 payments
  9. CIBINQO $572 28 payments
  10. XOLAIR $571 49 payments
  11. Other $6,879 327 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

657

Median for Allergy/ Immunology: 449

Drug cost

$329,535

Median for Allergy/ Immunology: $169,700

Branded share of claims

23.9%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xolair Omalizumab Brand 71 $202,343
Dupixent Pen Dupilumab Brand 13 $52,674
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 41 $49,886
Breo Ellipta Fluticasone/Vilanterol Brand 16 $11,093
Epinephrine Generic 16 $3,799
Azelastine Hcl Generic 93 $2,969
Fluticasone Propionate Generic 155 $2,058
Ipratropium Bromide Generic 55 $1,986
Levocetirizine Dihydrochloride Generic 16 $1,009
Albuterol Sulfate Hfa Albuterol Sulfate Brand 16 $466

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$46,844

Medicare's payments for the services billed

Medicare patients

130

Average age 70

Services billed

4,793

87 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 47%
Diabetes 36%
Ischemic heart disease 27%
COPD 24%
Depression 24%
Cancer 15%
Osteoporosis 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $257
$257 13 —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $190
  • Amgen Inc. $54
$245 — —
NUCALA
  • GlaxoSmithKline, LLC. $231
$231 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $183
$183 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $154
$154 71 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

651 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record